News

About 120 neurotechnology industry professionals attended the 20th anniversary Neurotech Leaders Forum earlier this month—roughly half in person and half on-line. The two day event, which took place in San Francisco, CA, was produced , the publisher of this newsletter. Neurotech Reports editor James Cavuoto opened the conference with a look back at the first Neurotech Leaders Forum in 2001, when the industry was just beginning to emerge.

Several new and emerging manufacturers of neuromodulation systems have chosen to integrate extended reality (XR)—which encompasses virtual reality and augmented reality—into their new therapeutic approaches. The new strategies deliver indirect stimulation of the nervous system, utilizing the patient’s natural sensory pathways. Cognixion, a Santa Barbara, CA startup, recently raised $12 million in s…

Several new and emerging manufacturers of neuromodulation systems have chosen to integrate extended reality (XR)—which encompasses virtual reality and augmented reality—into their new therapeutic approaches. The new strategies deliver indirect stimulation of the nervous system, utilizing the patient’s natural sensory pathways. Cognixion, a Santa Barbara, CA startup, recently raised $12 million in s…

Neurotech Reports, the publisher of Neurotech Business Report, announced the winners of the 2021 Gold Electrode Awards during the 20th Anniversary Neurotech Leaders Forum, which took place November 8-9 in San Francisco and also via Zoom. The award for best new product went to MicroTransponder Inc. for its Vivistim stroke rehabilitation system. The award for most promising startup went to Magnus Medical, which is developing a new form of magnetic stimulation to treat psychiatric disorders.

Neurotech Reports, the San Francisco, CA publisher of market intelligence for the healthcare industry, announced the launch of a new monthly newsletter covering the bioelectronic medicine industry, one of the newest and fastest growing industry segments. The publication, BioElectRx Business Report , is the first industry newsletter devoted to bioelectronic medicine, which refers to the therapeutic use of electrical or other forms of stimulation, rather than drugs, to treat disorders.

One of the major topics of debate at the 2021 Neurotech Leaders Forum, which took place earlier this month, was the question of whether the recent spate of success that the neuromodulation industry has seen in the last year or two was too much of a good thing. During an editorial panel featuring this editor, senior consulting editor Jeremy Koff, and contributing editor Jo Jo Platt, the panelists an…

Neurotech Reports, the publisher of this newsletter, updated the agenda for the 20th anniversary Neurotech Leaders Forum, which will take place in San Francisco on November 8-9, 2021. The event will also include speakers and attendees who prefer to participate via videoconference. Executives from several new and emerging neurotech firms will present at the conference. These include Brett Wingeier,…

b y James Cavuoto, editor October 2021 issue One of the challenges confronting neural engineers developing enhanced DBS systems is prolonging the effect of the stimulation. This would not only lead to longer battery life and reduce the need for subsequent surgeries, it would also likely improve the efficacy of DBS therapy. A team of researchers at Carnegie Mellon University recently reported in Sci…

Representatives from the neurotechnology industry, clinicians, and academics assembled with 32 students, post-docs, and neurotech entrepreneurs for the 2021 Cleveland NeuroDesign Entrepreneurs Workshop. The weekend event was held on the campus of Case Western Reserve University, which sponsored the workshop along with the Cleveland Clinic. The would-be entrepreneurs were grouped into eight teams of four and tasked with building a startup to address an unmet clinical need.

As we prepare for the 20th anniversary Neurotech Leaders Forum next month, it’s fascinating to look back on how the neurotechnology industry has changed since the first Leaders Forum in 2001. That event, coming just a few weeks after the 9/11 attacks, was attended by about a dozen early neurotech professionals. Chief among the topics discussed at the inaugural meeting were what to call this new industry and what products would and wouldn’t be included.